Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Human telomerase reverse transcriptase in papillary thyroid cancer: gene expression, effects of silencing and regulation by BET inhibitors in thyroid cancer cells.

Maggisano V, Celano M, Lepore SM, Sponziello M, Rosignolo F, Pecce V, Verrienti A, Baldan F, Mio C, Allegri L, Maranghi M, Falcone R, Damante G, Russo D, Bulotta S.

Endocrine. 2019 Mar;63(3):545-553. doi: 10.1007/s12020-018-01836-2. Epub 2019 Jan 19.

PMID:
30661164
2.

Reading Cancer: Chromatin Readers as Druggable Targets for Cancer Treatment.

Mio C, Bulotta S, Russo D, Damante G.

Cancers (Basel). 2019 Jan 9;11(1). pii: E61. doi: 10.3390/cancers11010061. Review.

3.

Biological and molecular effects of bromodomain and extra-terminal (BET) inhibitors JQ1, IBET-151, and IBET-762 in OSCC cells.

Baldan F, Allegri L, Lazarevic M, Catia M, Milosevic M, Damante G, Milasin J.

J Oral Pathol Med. 2019 Mar;48(3):214-221. doi: 10.1111/jop.12824. Epub 2019 Jan 24.

PMID:
30618144
4.

BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.

Mio C, Gerratana L, Bolis M, Caponnetto F, Zanello A, Barbina M, Di Loreto C, Garattini E, Damante G, Puglisi F.

Int J Cancer. 2019 Feb 15;144(4):755-766. doi: 10.1002/ijc.31898. Epub 2018 Dec 4.

PMID:
30259975
5.

Effects of HuR downregulation on anaplastic thyroid cancer cells.

Allegri L, Mio C, Russo D, Filetti S, Baldan F.

Oncol Lett. 2018 Jan;15(1):575-579. doi: 10.3892/ol.2017.7289. Epub 2017 Oct 30.

6.

BET bromodomain inhibitor JQ1 modulates microRNA expression in thyroid cancer cells.

Mio C, Conzatti K, Baldan F, Allegri L, Sponziello M, Rosignolo F, Russo D, Filetti S, Damante G.

Oncol Rep. 2018 Feb;39(2):582-588. doi: 10.3892/or.2017.6152. Epub 2017 Dec 12.

PMID:
29251329
7.

Effects of nutraceuticals on anaplastic thyroid cancer cells.

Allegri L, Rosignolo F, Mio C, Filetti S, Baldan F, Damante G.

J Cancer Res Clin Oncol. 2018 Feb;144(2):285-294. doi: 10.1007/s00432-017-2555-7. Epub 2017 Dec 2.

PMID:
29197967
8.

Evaluation of somatic genomic imbalances in thyroid carcinomas of follicular origin by CGH-based approaches.

Baldan F, Mio C, Allegri L, Passon N, Lepore SM, Russo D, Damante G.

Minerva Endocrinol. 2018 Sep;43(3):285-293. doi: 10.23736/S0391-1977.17.02735-3. Epub 2017 Sep 7. Review.

PMID:
28880059
9.

A polymorphic GGC repeat in the NPAS2 gene and its association with melanoma.

Franzoni A, Markova-Car E, Dević-Pavlić S, Jurišić D, Puppin C, Mio C, De Luca M, Petruz G, Damante G, Pavelić SK.

Exp Biol Med (Maywood). 2017 Sep;242(15):1553-1558. doi: 10.1177/1535370217724093. Epub 2017 Aug 11.

10.

Targeting post-translational histone modifications for the treatment of non-medullary thyroid cancer.

Celano M, Mio C, Sponziello M, Verrienti A, Bulotta S, Durante C, Damante G, Russo D.

Mol Cell Endocrinol. 2018 Jul 5;469:38-47. doi: 10.1016/j.mce.2017.05.036. Epub 2017 Jun 2. Review.

PMID:
28579118
11.

Identification of tumorigenesis-related mRNAs associated with RNA-binding protein HuR in thyroid cancer cells.

Baldan F, Mio C, Allegri L, Conzatti K, Toffoletto B, Puppin C, Radovic S, Vascotto C, Russo D, Di Loreto C, Damante G.

Oncotarget. 2016 Sep 27;7(39):63388-63407. doi: 10.18632/oncotarget.11255.

12.

Expression of PAX8 Target Genes in Papillary Thyroid Carcinoma.

Rosignolo F, Sponziello M, Durante C, Puppin C, Mio C, Baldan F, Di Loreto C, Russo D, Filetti S, Damante G.

PLoS One. 2016 Jun 1;11(6):e0156658. doi: 10.1371/journal.pone.0156658. eCollection 2016.

13.

MCM5 as a target of BET inhibitors in thyroid cancer cells.

Mio C, Lavarone E, Conzatti K, Baldan F, Toffoletto B, Puppin C, Filetti S, Durante C, Russo D, Orlacchio A, Di Cristofano A, Di Loreto C, Damante G.

Endocr Relat Cancer. 2016 Apr;23(4):335-47. doi: 10.1530/ERC-15-0322. Epub 2016 Feb 24.

14.

Effects of BP-14, a novel cyclin-dependent kinase inhibitor, on anaplastic thyroid cancer cells.

Allegri L, Baldan F, Mio C, Puppin C, Russo D, Kryštof V, Damante G.

Oncol Rep. 2016 Apr;35(4):2413-8. doi: 10.3892/or.2016.4614. Epub 2016 Feb 5.

PMID:
26884249
15.

Epigenetic bivalent marking is permissive to the synergy of HDAC and PARP inhibitors on TXNIP expression in breast cancer cells.

Baldan F, Mio C, Lavarone E, Di Loreto C, Puglisi F, Damante G, Puppin C.

Oncol Rep. 2015 May;33(5):2199-206. doi: 10.3892/or.2015.3873. Epub 2015 Mar 23.

PMID:
25812606
16.

Synergy between HDAC and PARP Inhibitors on Proliferation of a Human Anaplastic Thyroid Cancer-Derived Cell Line.

Baldan F, Mio C, Allegri L, Puppin C, Russo D, Filetti S, Damante G.

Int J Endocrinol. 2015;2015:978371. doi: 10.1155/2015/978371. Epub 2015 Jan 29.

Supplemental Content

Loading ...
Support Center